Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octreotide in malignant intestinal obstruction

H S Pandha1, J Waxman

  • 1Department of Clinical Oncology, Hammersmith Hospital, London, UK.

Anti-Cancer Drugs
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.

Oncogene·2026
Same author

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Science in Focus - Oncolytic Viruses: New Multifunctional Immunotherapeutics.

Clinical oncology (Royal College of Radiologists (Great Britain))·2016
Same author

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Gene therapy·2016
Same author

Circulating microRNAs as potential new biomarkers for prostate cancer.

British journal of cancer·2013
Same author

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Oncogene·2013

Octreotide effectively palliates malignant intestinal obstruction by improving absorption and motility. Its ease of administration and minimal side effects make it a valuable option for advanced cancer patients.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Malignant intestinal obstruction is a distressing complication of advanced cancer.
  • Refractory cases present significant palliative care challenges.

Purpose of the Study:

  • To evaluate the efficacy of octreotide in palliating refractory malignant intestinal obstruction.
  • To explore the potential mechanisms of octreotide's action in this context.

Main Methods:

  • Review of existing literature on octreotide use in malignant intestinal obstruction.
  • Analysis of proposed mechanisms including effects on mucosal absorption, gastrointestinal motility, hormone levels, and anti-neoplastic activity.

Main Results:

  • Octreotide demonstrates effectiveness in palliating malignant intestinal obstruction.

Related Experiment Videos

  • Potential mechanisms include enhanced small bowel absorption, improved gastrointestinal motility, reduced gastrointestinal hormones, and direct anti-neoplastic effects.

    • Conclusions:

    • Octreotide is a viable therapeutic option for refractory malignant intestinal obstruction.
    • Its simple administration and favorable side effect profile warrant consideration in palliative cancer care.